Report date: Friday, July 31, 2026, before market open | Call: 2026Q2 Earnings Call
Colgate-Palmolive shares have had a strong run in 2026, rallying from roughly $78 in early January to the low-$90s heading into the print — a move of nearly 20% year-to-date, aided by better-than-feared Q1 results and a weaker dollar. The stock has drifted in a $88–$95 range since June as oil prices climbed back toward $90/bbl on Middle East and Black Sea supply disruptions, a dynamic directly relevant to Colgate's margin outlook.
Wall Street sentiment remains constructive: analyst ratings skew Buy/Strong Buy with almost no Sells, and price targets have been moving higher — Citi recently raised its target to $110 from $105. However, valuation is now a talking point. Zacks estimates note CL trades at roughly a 23x forward P/E, a premium to the household/personal-care products industry average (~18x), meaning the market is pricing in continued execution and leaving less room for a stumble.
Q1 2026 set the tone for this report. Colgate posted net sales up 8.4% and organic sales growth of 2.9% (including a 0.6-point drag from the exit of the private-label pet food business), comfortably ahead of the Street's 2.1% organic growth estimate. Base Business EPS of $0.97 beat the $0.94 consensus, while GAAP EPS fell 6% to $0.80 due to Strategic Growth and Productivity Program (SGPP) charges. Gross margin, however, slipped 20 basis points to 60.6%.
The key debate coming out of Q1 was the geographic split: Latin America (+5.4% organic), EMEA (+3.5%) and Asia Pacific (+5.6%, led by improving China/Hawley & Hazel execution and India) all grew nicely, while North America organic sales fell 2.2%, with operating profit down sharply (-28%) on tariff exposure and higher raw material costs. Management framed North America as needing a "strategy reset" — new innovation, revenue growth management (RGM), and promotional fixes — with improvement expected to build through the year rather than snap back immediately.
The other major Q1 development: management flagged an incremental $300 million of raw material and logistics cost inflation for 2026 (about two-thirds raw materials, one-third logistics), driven by oil-linked inputs (resins, petrochemicals, fats/oils, up >20% y/y) and ocean/land freight (up ~10% y/y), built on an assumption of ~$110/bbl oil for the balance of the year. That single item is why full-year gross margin guidance flipped from "up" to "down," even as sales and EPS guidance were held.
1. Oil/commodity trajectory vs. guidance. Brent and WTI have rallied sharply into late July (Brent near $90/bbl, up roughly 25% over the trailing month amid Caspian Pipeline Consortium disruptions and broader Middle East tension) — running close to, or above, the ~$110 average oil assumption embedded in guidance for raw materials, but a level that still represents real upside cost pressure versus Q1's planning base. If management reiterates margin/EPS guidance despite the move in oil, it will be read as a confidence signal; any hint of trimming would likely hit the stock given how central this issue was to the Q1 call.
2. North America trajectory. This is the number everyone will be watching. Management explicitly called for sequential improvement in North America volumes and share as new innovation (Home Care and Personal Care) and shelf resets — delayed in Q1 — flow through, alongside a more aggressive promotional/RGM response to competitive couponing. Confirmation of a genuine inflection (versus another quarter of declines) is probably the single biggest swing factor for the stock reaction.
3. Emerging-market momentum. Latin America (Mexico/Brazil-led), EMEA, and Asia Pacific (China/Hawley & Hazel turnaround, India) were the growth engines in Q1. Investors will want to see this broad-based strength — balanced between volume and pricing — continue, since emerging markets carry higher structural growth and margin-accretion potential for Colgate.
4. Hill's Pet Nutrition. Hill's delivered standout results in Q1 (ex-private-label organic growth of 4.8%, U.S. growth of 5%, against a roughly flat category) driven by Science Diet, Prescription Diet, and share gains across most channels except dry dog food. Management guided the private-label pet food exit drag to fade to just 20–30 bps company-wide in Q2 before disappearing in the back half — worth confirming, since it directly affects the segment's reported organic growth optics.
5. Pricing vs. volume balance and innovation cadence. Management has signaled more pricing action is coming, ideally paired with innovation (premium launches like the "purple" toothpaste platform, Home Care adjacencies, Suavitel relaunch) to protect volume. Watch whether Q2 shows the industry-wide pricing catch-up management predicted as peers also face the same input-cost inflation.
6. SGPP productivity program. Colgate expanded its Strategic Growth and Productivity Program in Q1, raising cumulative pretax charges to $350–550 million (from $200–300 million) and targeting $200–300 million of annual run-rate savings, weighted to 2027–2028. Any additional color on pull-forward of savings to help offset near-term cost inflation would be a positive read.
7. Capital returns. Colgate raised its quarterly dividend to $0.53/share (its 63rd consecutive annual increase) with an ex-dividend date of July 20, 2026, and continued share buybacks ($306 million in Q1) alongside free cash flow growth (Q1 FCF before dividends of $609 million, up 28% y/y). Continued capital return discipline is a low-drama but important pillar of the bull case.
Colgate heads into Q2 2026 with consensus looking for roughly $5.35 billion in revenue and $0.95 in EPS, a continuation of the emerging-markets-led, North-America-lagging pattern seen in Q1. The company has a credible beat-and-raise track record (four straight EPS beats) and multiple self-help levers (RGM, pricing, SGPP savings, Hill's momentum), but the market's main focus will be twofold: (1) tangible evidence that North America is inflecting per management's promised "sequential improvement," and (2) whether rising oil prices force yet another cut to margin guidance just three months after the last one. With the stock trading at a premium multiple and near 52-week highs, the bar for a positive reaction is arguably higher than the bar for merely "in-line" results.